• Kelly N Michelson, Gary Reubenson, Scott L Weiss, Julie C Fitzgerald, Kate K Ackerman, LeeAnn Christie, Jenny L Bush, Vinay M Nadkarni, Neal J Thomas, Mark S Schreiner, and Sepsis Prevalence, Outcomes, and Therapy (SPROUT) Study Investigators and Pediatric Acute Lung Injury and Sepsis Investigators Network.
• Division of Pediatric Critical Care Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, IL.
• Pediatr Crit Care Me. 2018 Apr 1; 19 (4): e180-e188.

ObjectivesDuplicative institutional review board/research ethics committee review for multicenter studies may impose administrative burdens and inefficiencies affecting study implementation and quality. Understanding variability in site-specific institutional review board/research ethics committee assessment and barriers to using a single review committee (an increasingly proposed solution) can inform a more efficient process. We provide needed data about the regulatory oversight process for the Sepsis PRevalence, OUtcomes, and Therapies multicenter point prevalence study.DesignSurvey.SettingSites invited to participate in Sepsis PRevalence, OUtcomes, and Therapies.SubjectsInvestigators at sites that expressed interest and/or participated in Sepsis PRevalence, OUtcomes, and Therapies.InterventionsNone.Measurements And Main ResultsUsing an electronic survey, we collected data about 1) logistics of protocol submission, 2) institutional review board/research ethics committee requested modifications, and 3) use of a single institutional review board (for U.S. sites). We collected surveys from 104 of 167 sites (62%). Of the 97 sites that submitted the protocol for institutional review board/research ethics committee review, 34% conducted full board review, 54% expedited review, and 4% considered the study exempt. Time to institutional review board/research ethics committee approval required a median of 34 (range 3-186) days, which took longer at sites that required protocol modifications (median [interquartile range] 50 d [35-131 d] vs 32 d [14-54 d)]; p = 0.02). Enrollment was delayed at eight sites due to prolonged (> 50 d) time to approval. Of 49 U.S. sites, 43% considered using a single institutional review board, but only 18% utilized this option. Time to final approval for U.S. sites using the single institutional review board was 62 days (interquartile range, 34-70 d) compared with 34 days (interquartile range, 15-54 d) for nonsingle institutional review board sites (p = 0.16).ConclusionsVariability in regulatory oversight was evident for this minimal-risk observational research study, most notably in the category of type of review conducted. Duplicative review prolonged time to protocol approval at some sites. Use of a single institutional review board for U.S. sites was rare and did not improve efficiency of protocol approval. Suggestions for minimizing these challenges are provided.

21 keywords...

hide…